CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 14, 2005
(Date of
report)
CARACO PHARMACEUTICAL LABORATORIES, LTD.
(Exact name of registrant as specified in
its charter)
|
Michigan (State or other jurisdiction of incorporation) |
0-24676 (Commission file number) |
38-2505723 (I.R.S. employer identification no.) |
1150 Elijah McCoy
Drive, Detroit, Michigan 48202
(Address of principal executive offices)
(313)
871-8400
(Registrant’s telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |_| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |_| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12) |
| |_| | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |_| | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
(a) Not Applicable;
(b) On April 14, 2005, William C. Brooks resigned as a director of Caraco because his business and other activities did not leave him sufficient time for future meetings of the Board. Mr. Brooks was one of the three independent directors of the Company. The Company is actively searching for a new independent director to bring it into compliance with the Amex requirement that it have a minimum of three independent directors on its audit committee.
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 20, 2005 |
By: /s/ Jitendra N. Doshi ———————————————— Jitendra N. Doshi Chief Executive Officer ———————————————— |